(BPT) - Polar vortexes are out of sight and, spring has officially sprung. Family weekend brunches and scenic bike rides are on the horizon with brighter days ahead, but the warmer weather may also bring troubling rosacea flare-ups, leading some to avoid these memorable moments.,
Rosacea affects an estimated 16 million Americans, yet many are unaware that their symptoms may be due to this chronic inflammatory skin condition., With Rosacea Awareness Month upon us, it’s the perfect time to get “in the know” about this common yet misunderstood condition, which may cause facial redness and flushing, along with bumps and blemishes, facial burning and/or stinging., Spring is also commonly referred to as “rosacea season” according to the National Rosacea Society, thanks to its temperature changes, increased sun exposure, outdoor activity and seasonal allergies, all of which may be potential triggers for rosacea symptoms.,
Although rosacea may seem overwhelming, there are ways to manage this condition. Here are a few tips to understand rosacea signs and achieve the worry-free attitude that comes with clearer spring skin:
- Study the symptoms: Rosacea typically first appears after the age of 30. It can be difficult to identify because rosacea is easily mistaken for other skin conditions like acne. Over 30 and still suffering from breakouts that resemble pimples? Suffering from a sunburn that just doesn’t seem to fade? Take another look – it may be the bumps and blemishes or persistent redness of rosacea. People with rosacea may also experience visible blood vessels, thickened skin and/or bloodshot eyes.
- Avoid triggers: Rosacea flare-ups can be caused by everyday occurrences such as exercise, spicy foods, alcohol consumption, sun exposure, emotional stress and hot or cold weather. Make sure to be on the lookout for any patterns in symptoms.
- Ask your dermatologist: When in doubt, ask a board-certified dermatologist for help. They can confirm a rosacea diagnosis and find a tailored prescription treatment regimen to meet your skin needs. There are prescription treatment options available that are proven to reduce rosacea symptoms and help achieve clearer skin.
Treatment options for rosacea include Soolantra® (ivermectin) Cream, 1%, a gentle yet powerful topical cream that in clinical trials was proven to start working in as little as two weeks to help reduce the bumps and blemishes of rosacea., Another treatment option is Oracea® (doxycycline, USP) 40mg* Capsules, a convenient, once-daily treatment for the bumps and blemishes of rosacea. The active ingredient in Oracea Capsules is doxycycline, but unlike traditional antibiotic doses of doxycycline, the low-dose formulation of Oracea Capsules does not work by killing bacteria; instead it reduces the bumps and blemishes of rosacea because of its anti-inflammatory properties., That's important because rosacea is a chronic inflammatory skin condition, not a bacterial infection. In a nine month clinical study, Oracea Capsules were not shown to contribute to antibiotic resistance., Visit www.RosaceaRelief.com or talk to your doctor to learn more about rosacea and available treatment options. Make hiding springtime rosacea flare-ups a thing of the past, and instead, awaken newfound confidence thanks to clearer skin!
Important Safety Information
Indication: SOOLANTRA Cream is indicated for the treatment of inflammatory lesions of rosacea. Not for oral, ophthalmic or intravaginal use.
Adverse Events: In clinical trials with SOOLANTRA Cream, the most common adverse reactions (incidence = 1 %) included skin burning sensation and skin irritation.
Indication: ORACEA Capsules are indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. ORACEA Capsules do not lessen the facial redness caused by rosacea.
Adverse Events: In controlled clinical studies, the most commonly reported adverse events (>2%) in patients treated with ORACEA Capsules were nasopharyngitis, sinusitis, diarrhea, hypertension and aspartate aminotransferase increase.
Warnings/Precautions: ORACEA Capsules should not be used to treat or prevent infections. ORACEA Capsules should not be taken by patients who have a known hypersensitivity to doxycycline or other tetracyclines. ORACEA Capsules should not be taken during pregnancy, by nursing mothers, or during tooth development (up to the age of 8 years). Although photosensitivity was not observed in clinical trials, ORACEA Capsules patients should minimize or avoid exposure to natural or artificial sunlight. The efficacy of ORACEA Capsules treatment beyond 16 weeks and safety beyond 9 months have not been established.
*30 mg immediate release & 10 mg delayed release beads
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
All trademarks are the property of their respective owners.
 National Rosacea Society. Rosacea Triggers Survey. https://www.rosacea.org/patients/materials/triggersgraph.php. Accessed on March 6, 2019.
 National Rosacea Society. All About Rosacea. https://www.rosacea.org/patients/allaboutrosacea.php. Accessed on March 6, 2019.
 National Rosacea Society. Spring Forward, Not Backwards With Your Rosacea. https://www.rosacea.org/blog/2014/march/spring-forward-not-backwards-with-your-rosacea. Accessed on March 6, 2019.
 National Rosacea Society. Rosacea Awareness Month Aims To Demystify Widespread Disorder. https://www.rosacea.org/rosacea-review/1999/spring/rosacea-awareness-month-aims-to-demystify-widespread-disorder. Accessed on March 6, 2019.
 Soolantra® (ivermectin) cream, 1%, for topical use, Prescribing Information. 2014.
 Stein, L., et.al., Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. Journal of drugs in dermatology: JDD, 2014. 13(3), pp.316-323.
 Oracea (doxycycline) capsules for oral use. Prescribing Information. 2014.
 Valentín, Sheila, et al. Safety and efficacy of doxycycline in the treatment of rosacea. Clinical, cosmetic and investigational dermatology: CCID 2 (2009): 129.